ÂÜÀòÂÒÂ×

Dr. Elliott Sigal has served as a member of our board of directors since July 2020. He currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. He is a member of the Board of Directors for Adaptimmune, Surface Oncology and Affinia. He co-chairs the Scientific Advisory Board for Amgen and is a member of the Scientific Steering Committee for the Sean Parker Institute for Cancer Immunology. He previously served as a director of Spark Therapeutics and the Mead Johnson Nutrition Company. Dr. Sigal is a former Executive Vice President and Director of Bristol-Myers Squibb. He served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. Under his leadership, fourteen new medicines came to market including Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Eliquis (Stroke), and Yervoy, the first checkpoint inhibitor (Melanoma). He was instrumental in developing the company’s initial strategy in biologics and helping to build BMS research into a lead position in immuno-oncology, which is revolutionizing the practice of medicine in cancer. In 2012, Dr. Sigal was named the best R and D chief in the pharmaceutical industry by Scrip Intelligence. Dr. Sigal joined BMS in 1997 and held roles in both discovery and development before ascending to chief scientific officer. Positions prior to BMS included a faculty appointment at University of California, San Francisco (UCSF), senior executive roles at Syntex/Roche and CEO of the genomics firm, Mercator Genetics. Dr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at UCSF. Prior to medical school he received a B.S., M.S., and Ph.D. in industrial engineering from Purdue University.